Skip to main content

Astrana Health Inc

For the period ended Dec 31, 2023. Filed Feb 29, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 29, 2024

ASTH$34.50-11.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

ITEM 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ASTRANA HEALTH, INC.
Date: February 29, 2024By:/s/ Brandon K. Sim, M.S.
Brandon K. Sim, M.S.
Chief Executive Officer and President
(Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, Brandon K. Sim, M.S., as their true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934 this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SIGNATURETITLEDATE
By:/s/ Brandon K. Sim, M.S.Chief Executive Officer and President (Principal Executive Officer)February 29, 2024
Brandon K. Sim, M.S.
By:/s/ Chandan BashoChief Financial and Operating Officer (Principal Financial Officer)February 29, 2024
Chandan Basho
By:/s/ John VongChief Accounting Officer (Principal Accounting Officer)February 29, 2024
John Vong
By:/s/ Kenneth SimExecutive Chairman, DirectorFebruary 29, 2024
Kenneth Sim, M.D
By:/s/ Thomas LamVice Chairman, DirectorFebruary 29, 2024
Thomas Lam, M.D., M.P.H.
By:/s/ John ChiangDirectorFebruary 29, 2024
John Chiang
By:/s/ Weili DaiDirectorFebruary 29, 2024
Weili Dai
By:/s/ J. Lorraine EstradasDirectorFebruary 29, 2024
J. Lorraine Estradas
By:/s/ Mitchell KitayamaDirectorFebruary 29, 2024
Mitchell Kitayama
By:/s/ Linda MarshDirectorFebruary 29, 2024
Linda Marsh
By:/s/ Matthew MazdyasniDirectorFebruary 29, 2024
Matthew Mazdyasni
By:/s/ David SchmidtDirectorFebruary 29, 2024
David Schmidt
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.